Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex Science Coupled with Patience

Just ask Falconer and Mayomobile and other longs who understand the AVXL science and business strategy better than most why they are here. I believe in part it is because they are seeking investment returns magnitudes larger than what Wall Street produces.

Well, for me; exactly.

First, the Anavex science, particularly the unique way its molecules bind to the sigma-1 receptor protein and thereby activate it, causing a diversity of good “downstream” cell-health processes actually works. No other approach to treating Parkinson’s and Alzheimer’s comes close.

But anyone who knows how drugs work in the central nervous system (CNS) knows that virtually every one of those drugs produce AEs, “adverse events” — side effects. Many are severe and can compromise or terminate the drug’s therapy. Blarcamesine (Anavex 2-73), however, has never produced AEs of any consequence. For the drug, two favorable things: a) the drug actually produces favorable therapeutic outcomes (as shown in every clinical trial, in both early murine, lab rodent trials and subsequently in a variety of trials in real humans); and b) those favorable therapeutic outcomes are without side effects.

Fine and good. But the Anavex drug does not yet have approval for sales and therapeutic use. The drug is still in “development,” awaiting the completion of big clinical trials for three CNS diseases, the results of which will go to the FDA to allow sales and use approval. The three diseases are a) Rett syndrome, a genetic debility in girls, b) Parkinson’s disease dementia (PDD), and c) Alzheimer’s disease. Approval for blarcamesine’s treatment of either of the big two, PDD or Alzheimer’s, will generate literally billions of dollars of revenues for Anavex Life Sciences Corp.

I am a biologist; I understand the rudimentary cellular physiology involved in the three diseases and how blarcamesine is able to restore normal processes in the neuron. Starting about five years ago I’ve accumulated an AVXL position of several thousand shares. From the start my position has increased in value. I’m pleased. But I don’t anticipate ever selling a single share; my reward will be the dividends I’ll be collecting for the rest of my years. I’m not a day-trader or stock speculator. Many who post here tell their successes or frustrations with those approaches. But I’m a long-term investor, aiming eventually for dividends. That approach requires patience. From the start I looked out to 2023 before the Anavex drug could be approved by the FDA and corporate revenues would ensue.